Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2024-06-20 00:00:00 ET · period of report 2024-06-17 · accession 0001819790-24-000089 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-20 | 2024-06-17 | TARS | Farrow Jeffrey S | See Remarks | M - OptEx | — | +27.9K | 28.6K | +3,983% | — |
| D | 2024-06-20 | 2024-06-18 | TARS | Farrow Jeffrey S | See Remarks | S - Sale+OE | $27.47 | -10.4K | 18.1K | -37% | -$286.9K |
| D | 2024-06-20 | 2024-06-17 | TARS | Farrow Jeffrey S | See Remarks | M - OptEx | $0.00 | -27.9K | 83.6K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-17 | M | A | 27,881 | — | 28,581 | D | — | — | (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). |
| 2 | Common | Common Stock | 2024-06-18 | S | D | 10,445 | $27.47 | 18,136 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2024-06-17 | M | D | 27,881 | $0.00 | 83,644 | D | — · — to — | 27,881 Common Stock | (F3) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F4) RSUs granted on April 24, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. |